1-20 of 337
gemcitabine
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Rates and Management of Thrombocytopenia Due to Cancer Treatment in Advanced/Metastatic Female Genitourinary Malignancies

Joshua F Ransom, PhD, Aaron Galaznik, MDMBA, Emelly Rusli, Bruno Lempernesse, MS, Marc Berger, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4895.
https://doi.org/10.1182/blood-2019-129086
Published: 2019
Journal Articles

A Randomized Evaluation of Vinorelbine Versus Gemcitabine Chemotherapy Mobilization of Stem Cells in Myeloma Patients

Barbara Jeker, Sarah Farag, Urban Novak, Ulrike Bacher, Behrouz Mansouri Taleghani, Qiyu Li, Thomas Pabst, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1963.
https://doi.org/10.1182/blood-2019-127848
Published: 2019
Journal Articles

Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents

R. Alejandro Sica, MD, Michael A Spinner, John S Tamaresis, PhD, Ranjana H Advani, MD, Laura J Johnston, MD, Robert Lowsky, MD, Everett H Meyer, MD PhD, David B Miklos, MD PhD, Lori S Muffly, MD, Andrew R Rezvani, MD, Judith A Shizuru, MD PhD, Wen-Kai Weng, MD PhD, Robert S. Negrin, MD, Sally Arai, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2022.
https://doi.org/10.1182/blood-2019-131532
Published: 2019
Journal Articles

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Michael D. Jain, MD PhD, Anca Prica, MD, Ryan D. Morin, PhD, Vishal Kukreti, MD, Robert Kridel, MDMPH,PhD, Rob C. Laister, PhD, Li Meng, Christopher Rushton, Miguel Alcaide, Rashmi S. Goswami, MD PhD, Jan Delabie, MD PhD, Jessica Weiss, Tony Panzarella, M.Sc., P.Stat, Michael Crump, MD, David W. Scott, MBChB, PhD, John Kuruvilla, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2027.
https://doi.org/10.1182/blood-2019-131818
Published: 2019
Journal Articles

BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression

Paul J. Hampel, MD, Timothy G. Call, MD, Sara J. Achenbach, Kari G Rabe, Wei Ding, MD PhD, Eli Muchtar, MD, Saad S. Kenderian, MD, Yucai Wang, MD PhD, Amber Koehler, PA-C, MS, Amie Fonder, PA-C, MS, Jose F. Leis, MD PhD, Susan M. Schwager, Daniel L. Van Dyke, PhD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Sameer A. Parikh, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3050.
https://doi.org/10.1182/blood-2019-125411
Published: 2019
Journal Articles

Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Jake R. Schade, BA, Charles Kim, MD, Esther Drill, PhD, Annie Qiu, BA, Connie Lee Batlevi, MD PhD, Philip Caron, MD PhD, Donald Steven Colbourn, MD, Audrey Hamilton, MD, Paul A. Hamlin, MD, Steven M. Horwitz, MD, Andrew M. Intlekofer, MD PhD, Erel Joffe, MDMSc, Gottfried R. von Keudell, MD PhD, Anita Kumar, MD, Ariela Noy, MD, Michelle Okwali, MPH, Colette Owens, MD, M. Lia Palomba, MD, Ildefonso Rodriguez-Rivera, MD, Craig S. Sauter, MD, Heiko Schoder, MD, David J. Straus, MD, Santosha Vardhana, MD PhD, Anas Younes, MD, Andrew D. Zelenetz, MD PhD, Matthew J Matasar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2904.
https://doi.org/10.1182/blood-2019-122760
Published: 2019
Journal Articles

Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre

John Radford, Ellie White, Felipe A. Castro, PhD, Anshuman Chaturvedi, FRCPath, Nathalie Spielewoy, PhD, Adam Gibb, MBBS, Andy Surinach, MPH, Kim Linton, PhD, Aijing Shang, MD PhD, Michael Wenger, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2917.
https://doi.org/10.1182/blood-2019-123664
Published: 2019
Journal Articles

Real World Outcomes of Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation and Receive Commercially-Available Salvage Therapy

Emily C. Ayers, MD, David J Margolis, MD, Phyllis A. Gimotty, PhD, Daniel J. Landsburg, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2893.
https://doi.org/10.1182/blood-2019-128815
Published: 2019
Journal Articles

Lisocabtagene Maraleucel (liso-cel) for Treatment of Second-Line Transplant Noneligible (TNE) Relapsed/Refractory (R/R) Aggressive Non-Hodgkin Lymphoma (NHL): Initial Results from the PILOT Study

Alison R. Sehgal, MD, John Godwin, John Pribble, Lei Wang, PhD, Jerill Thorpe, BSc, Gerhard C. Hildebrandt, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2882.
https://doi.org/10.1182/blood-2019-127658
Published: 2019
Journal Articles

High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma

Alison J. Moskowitz, MD, Gunjan L. Shah, MDMS, Heiko Schoder, MD, Helen Hancock, ANP, Theresa Davey, MMSc, PA-C, Christopher Joong, BS, Lauren Pomerantz, BS, Christine Jarjies, MS, Anita Kumar, MD, Oscar B Lahoud, MD, Connie Lee Batlevi, MD PhD, Paul A. Hamlin, MD, David J. Straus, MD, Ildefonso Rodriguez-Rivera, MD, Colette Owens, MD, Philip Caron, MD PhD, Donald Steven Colbourn, MD, Andrew M. Intlekofer, MD PhD, Audrey Hamilton, MD, Steven M. Horwitz, MD, Erel Joffe, MDMSc, M. Lia Palomba, MD, Ariela Noy, MD, Matthew J Matasar, MD, Santosha Vardhana, MD PhD, Gottfried R. von Keudell, MD PhD, Joachim Yahalom, MD, Anas Younes, MD, Andrew D. Zelenetz, MD PhD, Craig H. Moskowitz
Journal: Blood
Blood (2019) 134 (Supplement_1): 2837.
https://doi.org/10.1182/blood-2019-127575
Published: 2019
Journal Articles

Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen

Xinhua Wang, MD PhD, Lei Zhang, Xiangli Liu, Xin Li, Ling Li, Xiaorui Fu, Zhenchang Sun, Jingjing Wu, Xudong Zhang, Jiaqin Yan, Yu Chang, Feifei Nan, Zhiyuan Zhou, Xiaolong Wu, Li Tian, Wencai Li, Hongwei Xue, Jinghua Wang, Liqun Zou, Liping Su, Yi Lu, Yanzhen Guo, Ken H. Young, Mingzhi Zhang
Journal: Blood
Blood (2019) 134 (Supplement_1): 463.
https://doi.org/10.1182/blood-2019-127811
Published: 2019
Journal Articles

Analysis of a Safety Run-in Cohort from Niveau, a Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma

Gerhard Held, MD, Corinne Haioun, MD PhD, Roch Houot, MD PhD, Philippe Gaulard, MD PhD, Thierry Molina, Andreas Rosenwald, MD, Marc André, Joerg Hoffmann, MD, Martin Dreyling, MD, Olivier Casasnovas, MD, Herve Maisonneuve, MD, Herve Tilly, MD PhD, Thomas Illmer, Stephanie Mayer, MD, Heinz Kirchen, MD, Paul La Rosée, MD, Markus Loeffler, MD, Marita Ziepert, PhD, Bettina Altmann, PhD, Viola Poeschel, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4085.
https://doi.org/10.1182/blood-2019-129347
Published: 2019
Journal Articles

Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Refractory/Relapsed (R/R) DLBCL. a Real Life Study in Patients Ineligible for Autologous Transplantation

Clarisse Cazelles, Karim Belhadj, Helene Vellemans, Vincent Camus, Christiane Copie, MD PhD, Liana Veresezan, MD, Emmanuel Itti, MD PhD, Stephanie Becker, MD, Muriel verlinde Carvalho, Jehan Dupuis, MD, Fabien Le Bras, Francois Lemonnier, MD PhD, Louise Roulin, MD, Taoufik El Gnaoui, Fabrice Jardin, Nicolas Mounier, MD, Herve Tilly, MD PhD, Corinne Haioun, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4115.
https://doi.org/10.1182/blood-2019-124143
Published: 2019
Journal Articles

Efficacy and Safety of PD-1 Inhibitor Plus GVD Chemotherapy in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMLBCL)

Qian Mei, PhD, Wenying Zhang, MD, Yang Liu, MD, Qingming Yang, MD, John E.J. Rasko, MBBS, PhD, Weidong Han, PhD MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4072.
https://doi.org/10.1182/blood-2019-121768
Published: 2019
Journal Articles

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Sang Eun Yoon, Seok Jin Kim, MD PhD, Tsai-Yun Chen, MD, Yong Park, Li Mei Poon, MBBS, MRCP, FRCPath, Young Rok Do, PhDMD, Ho Sup Lee, MD PhD, Won Sik Lee, MD PhD, Hong-ghi Lee, MD PhD, Soon Thye Lim, MBBS, MRCP, Hye Jin Kang, MD PhD, Cosphiadi Irawan, Jae Joon Han, MD PhD, Hyo Jung Kim, MD PhD, Cheolwon Suh, Hwan Jung Yun, MD, Soo Chin Ng, FRCP, Jae-Cheol Jo, MD PhD, Byeong Seok Sohn, MD PhD, Sung Yong Oh, Yeung-Chul Mun, MD, Daryl Tan, MBBS, MRCP, Seong Kyu Park, MD, Jae-Yong Kwak, MD PhD, Ye Guo, MD PhD, Huilai Zhang, MD, Jun Zhu, MD PhD, Weili Zhao, MD PhD, Won Seog Kim, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4035.
https://doi.org/10.1182/blood-2019-126637
Published: 2019
Journal Articles

Case Report: Sustained Remission Achieved from Anti-CD19 CAR T Cell Therapy Despite Prior Treatment with Anti-CD19 Antibody Tafasitamab (MOR208) in a Patient with Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Caspian Oliai, MD, Sven de Vos, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5360.
https://doi.org/10.1182/blood-2019-129371
Published: 2019
Journal Articles

R-CHOP Vs. R-CHOP+X for Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis

Oren Pasvolsky, MD, Alon Rozental, MD, Pia Raanani, MD, Anat Gafter-Gvili, MD, Ronit Gurion
Journal: Blood
Blood (2019) 134 (Supplement_1): 5331.
https://doi.org/10.1182/blood-2019-126013
Published: 2019
Journal Articles

Dual Epigenetic Agents Plus Rituximab-Gemcitabine-Oxaliplatin As a Salvage Treatment in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Changju Qu, PhD, Nana Ping, MD, PhD, Danqing Kong, MD, Fan Xia, MD, Depei Wu, MD PhD, Zhengming Jin, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5338.
https://doi.org/10.1182/blood-2019-128111
Published: 2019
Journal Articles

Niveau, a Phase 3 Study for Pts with B- or T-Cell Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivo lumab in Combination with G e mcitabine, Ox a liplatin (GemOx), Plus Rit u ximab (R) in Case of B-Cell Lymphoma

Gerhard Held, MD, Roch Houot, MD PhD, Abraham Avigdor, MD, Marc André, Anna Dabrowska-Iwanicka, Ulrich Jaeger, MD, Sanne Tonino, MD PhD, Marek Trneny, MD prof, Gomes da Silva Maria, MD PhD, Philippe Gaulard, MD PhD, Thierry Jo Molina, MD PhD, Andreas Rosenwald, MD, Grzegorz Rymkiewicz, Thierry Fest, Karin Tarte, PhD, Markus Loeffler, MD, Marita Ziepert, PhD, Bettina Altmann, PhD, Viola Poeschel, MD, Corinne Haioun, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5311.
https://doi.org/10.1182/blood-2019-129362
Published: 2019
Journal Articles

"Real-World" Peripheral T-Cell Lymphomas Experience in Portugal: Is There Reason for Optimism?

Ivan Dlouhy, Rita Gavancha, MD, Inês Coelho, MD, Catalina Gomez, MD, Inês Barbosa, MD, Susana Carvalho, MD, Maria Ceu Trindade, MD, Ana Filipa Moita, Gonçalo Esteves, MD, Paula Gameiro, Jose Cabecadas, Maria Silva, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5287.
https://doi.org/10.1182/blood-2019-124485
Published: 2019